Mesothelioma Treatment: Understanding Cytoreductive Surgery and HIPEC

Mesothelioma Treatment: Understanding Cytoreductive Surgery and HIPEC

Peritoneal mesothelioma is a rare cancer linked to asbestos exposure. It’s aggressive. However, a promising option combines cytoreductive surgery (CRS) with hot chemotherapy (HIPEC). A new article explains the CRS and HIPEC procedures and details their role in mesothelioma treatment. What is Cytoreductive Surgery (CRS)? Cytoreductive surgery removes as much tumor as possible. For peritoneal mesothelioma, it targets visible cancer in the abdomen, including organs like the intestines, liver, and spleen. Extensive surgery is crucial. It often involves removing multiple organs to eradicate all cancer cells. This aims to reduce the tumor to a microscopic level, making treatments more effective. Patient selection is vital. Only those with good health and a disease extent that can handle major surgery are considered….

Enhancing Survival for Patients with Pleural Mesothelioma: A Multimodal Treatment Approach
|

Enhancing Survival for Patients with Pleural Mesothelioma: A Multimodal Treatment Approach

Malignant pleural mesothelioma poses a significant health challenge. Linked to asbestos exposure, this aggressive cancer demands innovative treatment strategies. Recent research provides a promising approach to combatting mesothelioma. This multimodal treatment regimen could offer hope and improved outcomes for individuals battling this disease. A multimodal approach is when multiple treatments are used together. It is the most reliable way to improve survival in patients with malignant pleural mesothelioma. Understanding Pleural Mesothelioma Malignant pleural mesothelioma is an aggressive cancer. It is diagnosed late, which often presents unique challenges. While recent advancements like immunotherapy have emerged, survival rates remain low for patients. A new study focused on cytoreductive surgery combined with hyperthermic intrathoracic chemoperfusion (HITOC). This is a multimodal approach to mesothelioma…

Treatment Combination Used Most for Mesothelioma
| |

Treatment Combination Used Most for Mesothelioma

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is being used by doctors to treat malignant peritoneal mesothelioma (MPM) more often. This is the finding of a study published in the Annals of Surgical Oncology. This is promising news because research has shown the CRS-HIPEC can be an effective treatment for patients with MPM. Mesothelioma Caused by Asbestos Exposure MPM is caused by exposure to a toxic material called asbestos. Most doctors believe it is caused from ingestion of asbestos fibers and that microscopic asbestos fibers become embedded in the abdomen. After about 20-50 years, these fibers can cause inflammation and mutations that ultimately caused tumors to form. This cancer occurs in less than 1,000 people in the United States…

Largest Study Shows HIPEC Treatment Effective for Mesothelioma
| |

Largest Study Shows HIPEC Treatment Effective for Mesothelioma

Hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) could be an effective treatment for malignant peritoneal mesothelioma (MPM). This is the finding of one of the largest and longest studies on the use of CRS-HIPEC to treat MPM. Researchers from the Atrium Health Wake Forest Baptist Comprehensive Cancer Center looked at data from 111 patients over 28 years. Diagnosed with MPM MPM is an aggressive cancer caused by asbestos. Symptoms of MPM are usually noticed first in the abdomen or the gastrointestinal system. People might feel abdominal pain or swelling, fever, and night sweats. MPM occurs in less than 1,000 people in the United States every year and accounts for about 20-25% of all mesothelioma cases. Patients diagnosed with MPM have longer life expectancy…

Korean Cancer Doctors Embrace PIPAC for Mesothelioma
| | | |

Korean Cancer Doctors Embrace PIPAC for Mesothelioma

Five out of ten Korean oncologists surveyed feel positive about using an aerosolized chemotherapy system called PIPAC for mesothelioma and other types of cancer. PIPAC stands for pressurized intraperitoneal aerosol chemotherapy. The system turns liquid chemotherapy drugs into a spray that can be applied with a nebulizer. It was developed to treat surface malignancies like peritoneal mesothelioma that can be hard to treat with standard methods.  PIPAC can be used in conjunction with mesothelioma surgery or by itself as either a palliative or curative treatment.  The technology is still very new. Many doctors have never used it. But research conducted by the Seoul National University College of Medicine shows Korean doctors are ready to embrace it. How Spray-on Chemotherapy Works…

New Surgical Technique May Support Long-Term Peritoneal Mesothelioma Survival
|

New Surgical Technique May Support Long-Term Peritoneal Mesothelioma Survival

One of the nation’s top mesothelioma doctors says long-term peritoneal mesothelioma survival is possible with a far-reaching new surgical technique. Dr. Paul Sugarbaker is a surgeon with the Washington Cancer Institute in Washington, DC. He has studied peritoneal mesothelioma for decades.  In a new report, he outlines a case of long-term peritoneal mesothelioma survival in a female patient. The patient had cytoreductive surgery. The surgery included resection of the colonic mesentery. This is tissue that is not normally part of peritoneal mesothelioma surgery.  The case report shows the patient is still cancer-free four years after surgery with an “excellent” quality of life.  The Challenge of Peritoneal Mesothelioma Every year, about 2,500 Americans receive a diagnosis of mesothelioma. Peritoneal mesothelioma accounts…

Long Term Peritoneal Mesothelioma Survival with NIPEC
| | | | |

Long Term Peritoneal Mesothelioma Survival with NIPEC

A new report suggests that long term peritoneal mesothelioma survival may be possible with a treatment called NIPEC and the drug paclitaxel.  NIPEC stands for normothermic intraperitoneal chemotherapy. It is similar to the heated chemotherapy that many peritoneal mesothelioma patients now get. But NIPEC is delivered through a catheter over time and at room temperature.  The new article details the long term peritoneal mesothelioma survival of six patients on NIPEC with paclitaxel. It comes from one the nation’s leading experts in this form of mesothelioma, Paul Sugarbaker, MD.  Even though the sample size is small, Dr. Sugarbaker says the results are impressive enough to warrant further study.  HIPEC and Mesothelioma Treatment Peritoneal mesothelioma accounts for about 20 percent of mesothelioma…

Surgery for Peritoneal Mesothelioma Could Be Limited During Pandemic
| | |

Surgery for Peritoneal Mesothelioma Could Be Limited During Pandemic

It may be harder this year for patients who need it to get surgery for peritoneal mesothelioma.  An international group called RENAPE keeps track of peritoneal cancers like mesothelioma. The group advises doctors on the best treatment practices. The group is advising hospitals to tighten the criteria for who can get surgery for peritoneal mesothelioma during the pandemic.  “The Covid-19 pandemic is profoundly changing the organization of healthcare access,” say French doctors writing about the RENAPE recommendations. “This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources.” Mesothelioma Treatment Options Mesothelioma is a rare cancer associated with asbestos exposure. About a fifth of all mesothelioma cases are the peritoneal…

CRS/HIPEC Treatment Helps Double Survival Among Swedish Mesothelioma Patients
| | | |

CRS/HIPEC Treatment Helps Double Survival Among Swedish Mesothelioma Patients

A new report suggests that CRS/HIPEC treatment has helped to double the odds of surviving peritoneal mesothelioma in Sweden.  Researchers collected data from the Swedish National Cancer Registry. A total of 102 peritoneal mesothelioma cases were included from two separate 5-year time periods. The report shows that, since CRS/HIPEC treatment was introduced in Sweden, overall survival of peritoneal mesothelioma increased from 7 to 15 months. At 5 years, twice as many peritoneal mesothelioma patients were still alive. The researchers conclude that this is likely due, at least in part, to CRS/HIPEC treatment.  Surviving Peritoneal Mesothelioma Peritoneal mesothelioma is an aggressive cancer that starts on the membrane lining the abdomen. It is almost always caused by accidental swallowing of microscopic asbestos…

Unresectable Peritoneal Mesothelioma Becomes Operable After Bi-Directional Chemotherapy
| | | |

Unresectable Peritoneal Mesothelioma Becomes Operable After Bi-Directional Chemotherapy

French researchers have successfully operated on a man with unresectable peritoneal mesothelioma after treating him with bi-directional chemotherapy. Chemotherapy is the most common treatment for unresectable peritoneal mesothelioma. Most mesothelioma patients have chemotherapy by IV infusion. But some cancer centers now offer another chemotherapy delivery method. Intraperitoneal chemotherapy bypasses the bloodstream. It lets doctors put higher doses of cancer-killing medicine at the site of a tumor. The French team combined the two types of chemotherapy in one patient. It shrunk the patient’s unresectable peritoneal mesothelioma tumor enough to perform surgery.  Two Types of Mesothelioma Chemotherapy With IV chemotherapy, medicine travels to the tumor through the bloodstream. It is one way of treating unresectable peritoneal mesothelioma. One drawback of IV chemotherapy…